Erasca revamps pipeline, laying off staff as it licenses cancer drugs from China and nabs $160M

Eras­ca is look­ing for a re­fresh as it drops sev­er­al ear­ly-stage can­cer as­sets, picks up new ones from Chi­na and rais­es cash to help push its lead can­di­date to the fin­ish line.

The San Diego biotech said late Thurs­day that it is de­pri­or­i­tiz­ing its ERK 1/2 in­hibitor ERAS-007 and pan-KRAS can­di­date ERAS-4. As for the EF­GR in­hibitor ERAS-801, pa­tient en­rol­ment will be paused ac­cord­ing to Mizuho an­a­lysts, cit­ing a con­ver­sa­tion with Eras­ca ex­ecs, but Eras­ca said the drug will be fur­ther ex­plored in in­ves­ti­ga­tor-led tri­als.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.